89 Clinical Predictors for Progression to Chronic Kidney Disease in Mesoamerican Nephropathy

2018 ◽  
Vol 71 (4) ◽  
pp. 537
2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Alessandro Bosi ◽  
Juan Jesus Carrero ◽  
Jung-Im Shin ◽  
Yunwen Xu ◽  
Morgan Grams ◽  
...  

Abstract Background and Aims Many adverse drug events are preventable, such as those potentially resulting from the prescription of nephrotoxic drugs to persons with chronic kidney disease (CKD). We here quantify the extent of contemporary nephrotoxic medication use in patients with CKD. Method In two observational cohorts of Swedish (Stockholm CREAtinine Measurements [SCREAM] project, Stockholm, Sweden) and U.S. (Geisinger Health System, Pennsylvania) adults with confirmed CKD stages G3-G5 undergoing routine care during 2016-2018, we explored the prescription (in U.S.) and dispensation (in Sweden) of 115 different ambulatory drugs with proven or purported nephrotoxicity during the 12 months following study inclusion. We evaluated the proportion of participants receiving nephrotoxic drugs, ranked main contributors and identified clinical predictors. Results In the Swedish cohort, there were 57880 patients (54.6% women) with median age of 80.00 (inter-quartile range [IQR]: 73.0-86.0) years and eGFR 48.9 ([IQR]: 39.9-55.0) mL/min/1.73 m2. In the U.S. cohort, there were 16255 patients (59% women) with median age of 76 years and eGFR 44 mL/min/1.73 m2. During observation, 20% (Sweden) and 17% (U.S.) of patients received at least one nephrotoxic drug. The top 3 potentially inappropriate nephrotoxic drugs identified were NSAIDs (9% and 11% of participants in U.S. and Sweden received it), antivirals (2.0% and 2.5%) and immunosuppressants (1.5% and 2.7%). Bisphosphonate use was common in Sweden (3.3% of participants), but not in U.S. (0.5%). Conversely, fenofibrates were common in U.S. (3.6%), but not in Sweden (0.13%). In adjusted analyses, patients with young age (<65 years old), women, or with CKD G3 were at higher risk of receiving nephrotoxic medications in both cohorts (P>0.05 for all). Notably, patients aware of their CKD (identified either by issued diagnosis or recent visit to a nephrologist), were at lower risk of nephrotoxic drug use (OR 0.87, 95% CI 0.82-0.92 in Sweden and 0.89, 95% CI 0.81-1.01 in U.S.). Conclusion In two geographically distinct health systems, one in five patients with CKD received potentially inappropriate nephrotoxic medications, mainly NSAIDs. Strategies to increase CKD awareness and physician’s knowledge of drug nephrotoxicity may reduce inappropriate ambulatory prescriptions and prevent iatrogenic kidney injury.


2018 ◽  
Vol 94 (6) ◽  
pp. 1205-1216 ◽  
Author(s):  
Rebecca S.B. Fischer ◽  
Chandan Vangala ◽  
Sreedhar Mandayam ◽  
Denis Chavarria ◽  
Ramón García-Trabanino ◽  
...  

Medicina ◽  
2020 ◽  
Vol 56 (5) ◽  
pp. 213
Author(s):  
Bogdan Marian Sorohan ◽  
Andreea Andronesi ◽  
Gener Ismail ◽  
Roxana Jurubita ◽  
Bogdan Obrisca ◽  
...  

Background and Objectives: Pregnant women with chronic kidney disease (CKD) are at high risk of adverse maternal and fetal outcomes. Preeclampsia (PE) superimposed on CKD is estimated to occur in 21%–79% of pregnancies. Both conditions share common features such as proteinuria and hypertension, making differential diagnosis difficult. Objective: The aim of this study was to evaluate the incidence and the clinical-biological predictors of preeclampsia in pregnant women with CKD. Material and Methods: We retrospectively analyzed 34 pregnant women with pre-existing CKD admitted to our department between 2008 and 2017. Results: Among the 34 patients, 19 (55.8%) developed PE and the mean time of occurrence was 31.26 ± 2.68 weeks of gestation. The median value of 24-h proteinuria at referral was 0.87 g/day (interquartile range 0.42–1.50) and 47.1% of patients had proteinuria of ≥1 g/day. Patients with PE tended to be more hypertensive, with a more decreased renal function at referral and had significantly higher proteinuria (1.30 vs. 0.63 g/day, p = 0.02). Cox multivariate analysis revealed that proteinuria ≥1 g/day at referral and pre-existing hypertension were independently associated with PE (adjusted hazard ratio = 4.10, 95% confidence interval: 1.52–11.02, p = 0.005, adjusted hazard ratio = 2.62, 95% confidence interval: 1.01–6.77, p = 0.04, respectively). The cumulative risk of PE was significantly higher in pregnant women with proteinuria ≥1 g/day at referral (log-rank, p = 0.003). Proteinuria ≥ 1 g/day at referral and pre-exiting hypertension predicted PE development with accuracies of 73.5% and 64.7%, respectively. Conclusions: Pregnant patients with pre-existing CKD are at high risk of developing preeclampsia, while proteinuria ≥ 1 g/day at referral and pre-existing hypertension were independent predictors of superimposed preeclampsia.


2018 ◽  
Vol 41 (5) ◽  
pp. 660-665 ◽  
Author(s):  
Venkatesh Ravi ◽  
Fady Iskander ◽  
Abhimanyu Saini ◽  
Carolyn Brecklin ◽  
Rami Doukky

2015 ◽  
Vol 72 (10) ◽  
pp. 714-721 ◽  
Author(s):  
Catharina Wesseling ◽  
Berna van Wendel de Joode ◽  
Jennifer Crowe ◽  
Ralf Rittner ◽  
Negin A Sanati ◽  
...  

2014 ◽  
Vol 71 (Suppl 1) ◽  
pp. A27.1-A27 ◽  
Author(s):  
Catharina Wesseling ◽  
Berna van Wendel de Joode ◽  
Jennifer Crowe ◽  
Ralf Rittner ◽  
Kristina Jakobsson

PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0193056 ◽  
Author(s):  
Julia Wijkström ◽  
Channa Jayasumana ◽  
Rajeewa Dassanayake ◽  
Nalin Priyawardane ◽  
Nimali Godakanda ◽  
...  

Nephrology ◽  
2016 ◽  
Vol 21 (10) ◽  
pp. 851-859 ◽  
Author(s):  
Mallika L Mendu ◽  
Andrew Lundquist ◽  
Ayal A Aizer ◽  
David E Leaf ◽  
Emily Robinson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document